Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,425 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy.
Zangrilli A, Caldarola G, Bernardini N, Bavetta M, Graceffa D, Bonifati C, Cantoresi F, Faleri S, Giordano D, Mariani M, Micheli A, Moretta G, Pirro F, Pagnanelli G, Panasiti V, Provini A, Richetta A, Sacchelli L, Bianchi L, Peris K. Zangrilli A, et al. Among authors: mariani m. Expert Opin Biol Ther. 2021 Sep;21(9):1291-1298. doi: 10.1080/14712598.2021.1948530. Epub 2021 Jul 18. Expert Opin Biol Ther. 2021. PMID: 34278889
Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.
Caldarola G, Zangrilli A, Bernardini N, Bavetta M, De Simone C, Graceffa D, Bonifati C, Faleri S, Giordano D, Mariani M, Micheli A, Moretta G, Pagnanelli G, Panasiti V, Provini A, Richetta A, Peris K, Bianchi L. Caldarola G, et al. Among authors: mariani m. Dermatol Ther. 2022 Jun;35(6):e15489. doi: 10.1111/dth.15489. Epub 2022 Apr 13. Dermatol Ther. 2022. PMID: 35385202 Free PMC article.
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study.
Caldarola G, Chiricozzi A, Megna M, Dapavo P, Giunta A, Burlando M, Malagoli P, Dini V, Mariani M, Fabbrocini G, Quaglino P, Bianchi L, Parodi A, Peris K, De Simone C. Caldarola G, et al. Among authors: mariani m. Expert Opin Biol Ther. 2023 Apr;23(4):365-370. doi: 10.1080/14712598.2023.2193288. Epub 2023 Mar 20. Expert Opin Biol Ther. 2023. PMID: 36927246
Long-Term Effectiveness of Brodalumab for the Treatment of Moderate-To-Severe Psoriasis: A Real-Life Multicenter Study of Up to 3 Years in a Real-Life Italian Cohort.
Caldarola G, Galluzzo M, Bernardini N, Botti E, De Luca E, De Simone C, Mariani M, Moretta G, Pallotta S, Campione E, Peris K. Caldarola G, et al. Among authors: mariani m. Dermatol Pract Concept. 2024 Apr 1;14(2):e2024152. doi: 10.5826/dpc.1402a152. Dermatol Pract Concept. 2024. PMID: 38810071 Free PMC article.
1,425 results